Respiratory syncytial virus: prospects for new and emerging therapeutics

Patricia A. Jorquera, Ralph A. Tripp

Research output: Contribution to journalReview articlepeer-review

60 Citations (Scopus)


Introduction: Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infections (LRTI) in infants, the elderly, and the immunocompromised. Although the development of a RSV vaccine has been a priority for >50 years, there is still no vaccine available. Treatment of RSV LRTI has remained mostly supportive, i.e. hydration and oxygenation. Palivizumab and ribavirin are the only options currently available for prevention and treatment of RSV infection, but evidence suggests that they are not fully effective. This creates a significant unmet medical need for new therapeutics for prevention and treatment of RSV worldwide. Areas covered: This article reviews the antiviral drugs and monoclonal antibodies (mAb) for RSV that are in different stages of clinical development. Expert commentary: Over the last 10 years, new antiviral drugs and mAb have shown clinical promise against RSV, and may become available in the coming years. Although the RSV fusion protein has been the most popular target for inhibitors and mAbs, new approaches targeting other viral proteins have shown promising results. To overcome the emergence of RSV escape mutants, combination antiviral therapy may be explored in the future.

Original languageEnglish
Pages (from-to)609-615
Number of pages7
JournalExpert Review of Respiratory Medicine
Issue number8
Publication statusPublished - 3 Aug 2017
Externally publishedYes


Dive into the research topics of 'Respiratory syncytial virus: prospects for new and emerging therapeutics'. Together they form a unique fingerprint.

Cite this